Dr. Asnat Raziel

My articles

My articles

Fatty liver risk assessment in the clinic: a protocol for the new drug era

Fatty liver risk assessment: from incidental finding to treatment decision

Metabolic fatty liver is no longer an incidental finding that ends with general advice to lose weight. Today, fatty liver risk assessment follows a structured clinical pathway for metabolic dysfunction-associated steatotic liver disease (MASLD). The pathway has three steps: initial risk stratification with FIB-4, a second-line assessment of liver stiffness and, for some patients, approved drug treatment.

You calculate FIB-4 from four values found in almost every medical file. In addition, within a year and a half the US Food and Drug Administration (FDA) approved two drugs for MASH with stage F2 to F3 fibrosis. Resmetirom received approval in 2024, and semaglutide followed in 2025. In 2026, Europe also approved both drugs. As a result, identifying fibrosis has become a treatment decision, not just a way to classify prognosis.

The new name changes the referral question

The term MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) requires at least one cardiometabolic risk factor. In other words, the definition no longer rests only on ruling out alcohol.

The disease progresses along a continuum. It starts with steatosis, that is, fat in the liver, and moves on to MASH (Metabolic dysfunction-Associated Steatohepatitis), or metabolic liver inflammation. From there, it may progress to fibrosis, cirrhosis and, in some cases, primary liver cancer.

Here is the key clinical point: the fibrosis stage determines prognosis, not the amount of fat. So when an ultrasound shows a fatty liver, the question is not only whether fat is present. The important question is what state the tissue beneath it is in. You can read more in my guide to liver fibrosis and its treatment.

Step one: metabolic and liver evaluation

The workup starts with the big picture, not a single test. It includes three components:

  • Blood tests: liver enzymes, blood count and platelets, glucose and HbA1c, lipid profile and kidney function.
  • Ruling out other causes: viral hepatitis, autoimmune disease, hemochromatosis, liver-toxic medications and significant alcohol intake.
  • Metabolic measures: weight, waist circumference, blood pressure, diabetes or prediabetes, abdominal obesity and abnormal blood lipids.

Keep in mind that normal liver enzymes do not rule out advanced disease. Many patients with advanced fibrosis have ALT and AST in the normal range. Therefore, a fatty liver risk assessment cannot rely on enzymes alone.

FIB-4 in fatty liver risk assessment: the formula and cutoffs

Today, FIB-4 is the best-established first-line screening tool for identifying the risk of advanced fibrosis. You calculate it from age, AST, ALT and platelet count:

FIB-4 = (Age × AST) ÷ (Platelets × √ALT)

Age is in years, enzymes in units per liter, and platelets in thousands per microliter. For example, take a 55-year-old woman with an AST of 40, an ALT of 50 and a platelet count of 220,000. Her score is about 1.41.

Here is how to interpret it, according to the American Association for the Study of Liver Diseases (AASLD) guidance, for ages 35 to 65:

  • Below 1.3: low risk of advanced fibrosis, and follow-up stays in primary care.
  • Between 1.3 and 2.67: an indeterminate zone that calls for a second-line assessment.
  • Above 2.67: suspected advanced fibrosis, usually with care from a liver specialist.

Adjusting for age and the tool’s limits

From age 65, the lower cutoff rises to 2.0 to avoid unnecessary referrals. However, the upper cutoff stays at 2.67. Below age 35, the score becomes less sensitive. That is why the AASLD recommends an additional assessment, such as elastography, in younger patients. Also, the score is not suitable for patients with an acute illness.

It is also important to be clear about what the tool cannot do. FIB-4 does not quantify fibrosis and does not replace a diagnosis. Its job is to screen: to rule out people at low risk and to move those who need a workup to the next step.

Step two in fatty liver risk assessment: liver stiffness

In patients above the low-risk cutoff, the preferred second-line test is vibration-controlled transient elastography (VCTE, FibroScan). An accepted alternative is the ELF test (Enhanced Liver Fibrosis), a panel of blood markers for fibrosis.

A stiffness value below 8 kilopascals helps rule out advanced fibrosis. On the other hand, higher values need interpretation in the clinical context and further workup. With very high values, we treat the patient as having advanced chronic liver disease until proven otherwise.

When there is uncertainty, or when results do not match the clinical suspicion, you can add MRI-based elastography. In selected cases, a liver biopsy is also necessary.

Fatty liver and lifestyle: gradual and measurable

Weight loss remains the most effective intervention. It helps to present it to patients as a ladder rather than a single target:

  • Losing about 5% of body weight reduces liver fat content.
  • At 7% to 10%, the chance of less inflammation rises.
  • A loss of 10% or more may also improve fibrosis in some patients.

Physical activity is a treatment in its own right, even when weight barely changes. The usual target is 150 to 300 minutes a week of aerobic activity, plus two to three strength sessions. Strength training matters most during rapid weight loss on medication. The goal is to reduce fat while preserving muscle and function, as I explained in my article on preserving muscle mass during weight loss.

When it comes to diet, the Mediterranean pattern is a good fit. It includes vegetables, legumes, fish, olive oil, nuts, whole grains and quality protein. At the same time, it is worth cutting back on sugary drinks, added sugar, ultra-processed food and refined carbohydrates.

Drug treatment: resmetirom

Resmetirom, sold as Rezdiffra, is a once-daily pill. It selectively activates the thyroid hormone receptor beta in the liver.

The MAESTRO-NASH trial enrolled 966 patients with biopsy-confirmed MASH and stage F1B, F2 or F3 fibrosis. The researchers randomly assigned them to resmetirom 80 mg, resmetirom 100 mg or placebo. At week 52, MASH resolved without worsening of fibrosis in 25.9% on 80 mg and 29.9% on 100 mg, compared with 9.7% on placebo.

Fibrosis improved by at least one stage in 24.2% and 25.9%, respectively, compared with 14.2% on placebo. In addition, LDL cholesterol fell by 13.6% and 16.3% by week 24. Diarrhea and nausea were more common than with placebo. The FDA granted accelerated approval in March 2024. The European Union approved it in August 2025 with conditional approval, for adults with MASH without cirrhosis and with F2 to F3 fibrosis.

Drug treatment: semaglutide

The ESSENCE trial tested semaglutide at 2.4 mg a week. It included 1,197 patients with biopsy-confirmed MASH and stage 2 or 3 fibrosis. The published analysis is a planned interim analysis at week 72, covering the first 800 patients.

MASH resolved without worsening of fibrosis in 62.9% on semaglutide, compared with 34.3% on placebo. Fibrosis improved without worsening of MASH in 36.8%, compared with 22.4%. Both outcomes together occurred in 32.7%, compared with 16.1%. Moreover, weight fell by an average of 10.5%, compared with 2.0% on placebo.

The FDA approved Wegovy for this indication in August 2025, also under accelerated approval. The European Union approved semaglutide for the same indication in March 2026 under the name Kayshild, and in the UK in July 2026. The second part of ESSENCE will look at liver events over 240 weeks. You will find more on the data in my article on Wegovy for fatty liver.

What to tell the patient

Regulators granted both indications based on biopsy results. They did not rely on long-term clinical outcomes, so the explanation to the patient should reflect that. In addition, you need to check registration status, indication and insurance coverage in Israel separately. Tirzepatide has also shown encouraging liver results, as I described in my article on Mounjaro and fatty liver, but it is not approved for this indication.

Fatty liver risk assessment, the heart and alcohol

Cardiovascular disease is the leading cause of death in this population. That is why controlling diabetes, blood pressure and blood lipids is not an add-on to liver care, but part of it. I discussed this link at length in my article on fatty liver and the heart.

Meanwhile, as liver disease progresses, cutting back on alcohol becomes more important. For patients with advanced fibrosis, the recommendation is complete abstinence. In the early stages, we tailor the advice to the risk level and the overall picture.

Long-term follow-up after fatty liver risk assessment

Even a patient with a low FIB-4 needs follow-up, as long as the metabolic risk factors remain. For patients with diabetes, prediabetes or two or more metabolic risk factors, repeat FIB-4 every one to two years. When metabolic risk is low, repeat the test every two to three years.

During follow-up, look at the whole picture: weight, waist circumference, blood pressure, HbA1c, lipid profile, liver enzymes and fibrosis assessment according to risk level.

Bottom line: metabolic fatty liver as an early marker

The clinical pathway is clear. First, start with a metabolic evaluation and blood tests, and calculate FIB-4. Then, as needed, refer for VCTE or ELF and determine the disease stage. Finally, build a personalized plan: nutrition, physical activity, muscle preservation and treatment of risk factors. For suitable patients, add approved drug treatment as well.

The great advantage of this approach is early detection, at a stage when we can still change the course of the disease. Metabolic fatty liver is not just an ultrasound finding. Rather, it is an early marker of metabolic health, and today we have the tools for fatty liver risk assessment, treatment and follow-up.

The information in this article is general and does not replace personal medical advice.

References

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Spare Me the Jab: Noninvasive Assessment of Patients with MASLD

Wegovy approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis

Rezdiffra – European Medicines Agency

Kayshild – European Medicines Agency

Semaglutide (Wegovy) approved to treat form of liver disease

Madrigal and Novo Nordisk, the drug manufacturers, funded the MAESTRO-NASH and ESSENCE trials.

fatty liver risk assessment - illustration of the liver and liver cells in the lab

Dr. Asnat Raziel